ACIU — AC Immune SA
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1651625 ·
Last close
$2.50
Market Cap
$248.57M
52W High
$4.00
52W Low
$2.10
ADV30
183,991
Next earnings
2026-11-04
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 15,113,000 | — | 1,193,000 | 1,874,000 | 150,401,000 | 27,757,000 | 115,232,000 |
| Mar 2026 | 1,119,000 | — | -14,788,000 | -14,801,000 | 137,421,000 | 19,169,000 | 105,887,000 |
| Dec 2025 | 338,000 | — | -14,406,000 | -14,373,000 | 154,251,000 | 26,795,000 | 109,367,000 |
| Sep 2025 | 939,000 | — | -15,699,000 | -15,858,000 | 171,607,000 | 27,741,000 | 109,163,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-69,262,000
Investing CF
$63,542,000
Financing CF
$-1,020,000
CapEx
$-900,000
Dividends Paid
—
Buybacks
$-5,000
EPS Diluted TTM
$-0.71
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-450,440,000
Inventory
—
Receivables
$13,645,000
ST Investments
$47,600,000
EBIT TTM
$-42,944,000
Pretax Income TTM
$-43,158,000
Interest Exp TTM
$214,000
Analysts
4
Yahoo Snapshot (yfinance, live)
Total Revenue
$17,509,000
EBITDA
$-42,479,000
Free Cash Flow
$-33,138,624
Enterprise Value
$203,163,328
Total Cash
$75,357,000
Total Debt
$4,102,000
Shares Out
99,426,932
Trailing EPS
$-0.53
Book Value
$0.44
ROE
-78.5%
ROA
-16.0%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 3,573,000 | -68,863,000 | -70,447,000 | 154,251,000 | 109,367,000 | 44,884,000 | -69,262,000 |
| Dec 2024 | 27,309,000 | -52,378,000 | -50,916,000 | 230,913,000 | 118,643,000 | 112,270,000 | 65,842,000 |
| Dec 2023 | 14,801,000 | -53,624,000 | -54,233,000 | 182,814,000 | 22,171,000 | 160,643,000 | -60,408,000 |
| Dec 2022 | 3,935,000 | -70,847,000 | -70,753,000 | 185,938,000 | 16,947,000 | 168,991,000 | -73,568,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$0.60
Max Pain — expiry 2026-11-20
max pain strike: $2.50 · spot: $2.50 · call oi: 1,897 · put oi: 581
Expected Move to 2026-11-20:
±$0.92
(37.00%) —
implied range
$1.58 –
$3.42
· ATM straddle on $2.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| QTTB | Q32 Bio Inc. | $248.28M | $8.34 | — |
| ZNTL | Zentalis Pharmaceuticals, Inc. | $249.93M | $2.64 | — |
| LFCR | LIFECORE BIOMEDICAL, INC. \DE\ | $244.15M | $6.45 | — |
| PRLD | Prelude Therapeutics Inc | $253.14M | $3.89 | — |
| VCRE | Vicore Pharma Holding AB | $253.48M | $9.00 | — |
News headlines (Yahoo Finance, 1h cache)
INSM Stock Slides on CFO Exit, Reiterates '26 Sales View
2026-10-06 14:29 · Yahoo
AGIO Stock Sinks 29% in Three Months: Here's What You Need to Know
2026-10-06 13:55 · Yahoo
PCRX Expands Exparel Commercial Reach in Europe Through Molteni Deal
2026-10-06 13:30 · Yahoo
Novartis Strengthens RNA Therapeutics Pipeline With $7.8B Abogen Deal
2026-10-05 15:21 · Yahoo
Ultragenyx's Gene Therapy for Sanfilippo Syndrome Wins EMA Validation
2026-10-05 14:46 · Yahoo
Novo's Denecimig BLA Review Delayed by FDA Facility Remediation Work
2026-10-05 14:36 · Yahoo
UTHR Prevails in LQDA's Yutrepia Patent Dispute, Stock Up Nearly 13%
2026-10-01 15:16 · Yahoo
Novo's Wegovy Pill Shows Weight Loss After Switching From Injections
2026-10-01 13:42 · Yahoo
Merck's Tulisokibart Meets Endpoints in Hidradenitis Suppurativa Study
2026-10-01 12:55 · Yahoo
NVO's Ozempic Outshines LLY's Mounjaro in Lowering Cardiovascular Risk
2026-09-30 17:34 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.